Sohomoy

United States Biologics Market Size, Share, In-Depth Analysis, Opportunity and Forecast 2026-2034

6 min read
0
Comments
172
Views

IMARC Group has recently released a new research study titled "United States Biologics Market Size, Share, Trends and Forecast by Source, Product, Disease, Manufacturing and Region, 2026-2034", offering a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.

United States Biologics Market Size & Share 2026-2034

The United States biologics market size was valued at USD 204.4 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 386.2 Billion by 2034, exhibiting a CAGR of 7.11% from 2026–2034. The market is primarily driven by the rapid adoption of bioprocessing technologies for efficiency, growing expansion of biosimilars addressing affordability, and rising AI integration in drug discovery, clinical trials, and manufacturing, collectively enhancing innovation, reducing costs, and improving access to advanced therapies.

According to the CDC, an estimated 129 Million Americans have at least one chronic disease, with 42% managing two or more and 12% dealing with at least five conditions, and chronic diseases account for 90% of the annual USD 4.1 Trillion healthcare expenditure, highlighting the need for innovative biologics. Growing R&D investments, supportive FDA frameworks such as fast-track approvals, and the adoption of personalized medicine continue to shape the market.

Key Market Statistics at a Glance

  • Base Year: 2025
  • Historical Years: 2020-2025
  • Forecast Period: 2026-2034
  • Base Year Market Size (2025): USD 204.4 Billion
  • Forecast Market Size (2034): USD 386.2 Billion
  • Growth Rate: CAGR of 7.11% (2026-2034)

Explore Opportunities in the United States Biologics Market: Download the IMARC Sample Report: https://www.imarcgroup.com/united-states-biologics-market/requestsample

Key Growth Drivers and Trends in the United States Biologics Market

Growth in the United States biologics market is being driven by the growing adoption of advanced bioprocessing technologies, including single-use bioreactors, continuous manufacturing, and high-throughput screening systems, which are streamlining manufacturing processes and reducing production costs. Rentschler Biopharma's Milford facility, operational since July 11, 2024, with four 2,000L single-use bioreactors, doubled cGMP capacity for complex biologics, supporting innovative therapies and global healthcare advancements.

One of the leading United States biologics market trends is the rapid expansion of the biosimilars segment, driven by growing demand for affordable alternatives to branded biologics, with the FDA's Biosimilar Approval Pathway allowing easier market entry and increased competition while decreasing treatment costs. On July 2, 2024, Sobi began a rolling BLA submission for SEL-212, a novel biologic aimed at serum urate levels in chronic refractory gout, reflecting continued pharmaceutical investment in biosimilar research and development.

Another key factor supporting market growth is the ongoing integration of artificial intelligence in biologics development, speeding up drug discovery, optimizing clinical trials, and enhancing production processes. AI-powered platforms analyze large datasets to identify promising biologic candidates, streamline patient recruitment, and improve trial efficiency, while also supporting quality control monitoring and predictive maintenance in bioprocessing.

Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=20441&flag=C

United States Biologics Industry Segmentation Insights

Breakup by Source:

  • Microbial: Serves as an efficient host system for producing recombinant proteins, enzymes, and vaccines, with E. coli and yeast systems ensuring high yield and cost-effective scalability.
  • Mammalian: Critical for producing complex biologics such as monoclonal antibodies, fusion proteins, and cell therapies, with CHO cell systems dominating this segment.
  • Others: Includes additional biologic production source systems serving specialized therapeutic applications.

Breakup by Product:

  • Monoclonal Antibodies: A mainstay of the market, widely used for cancer, autoimmune diseases, and infections, with continued innovation in antibody-drug conjugates and bispecific antibodies.
  • Vaccines: Growing rapidly, driven by advancements in mRNA technology, pandemic preparedness, and expanding research in cancer and personalized vaccines.
  • Recombinant Proteins: Widely used in treating diabetes, anemia, and growth disorders, with biosimilars improving accessibility and affordability.
  • Antisense, RNAi and Molecular Therapy: An advancing segment supporting precision-targeted treatment approaches.
  • Others: Includes additional biologic product categories serving diverse therapeutic needs.

Breakup by Disease:

  • Oncology: Leads the market given the significant occurrence of cancer, with monoclonal antibodies and immune checkpoint inhibitors transforming cancer therapy.
  • Immunological Disorders: Witnessing strong growth with rising incidence of rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
  • Cardiovascular Disorders: Gaining ground through monoclonal antibodies for cholesterol regulation, such as PCSK9 inhibitors.
  • Hematological Disorders: Supported by biologic therapies addressing blood-related conditions and rare disease treatment needs.
  • Others: Includes additional disease areas benefiting from biologic therapeutic advancements.

Breakup by Manufacturing:

  • Outsourced: Increasing as companies rely on contract research and manufacturing organizations for cost-efficient, scalable production and faster regulatory compliance.
  • In-House: Remains vital for companies prioritizing control over manufacturing processes, quality assurance, and intellectual property protection.

Breakup by Region:

  • Northeast: Driven by a concentration of leading biotechnology and pharmaceutical companies, particularly in Massachusetts and New York.
  • Midwest: Growing rapidly in biologics manufacturing, with significant contributions from Illinois and Indiana.
  • South: Benefits from major biopharmaceutical companies and favorable business climates in states like North Carolina and Texas.
  • West: Dominates biologics innovation, particularly in California, home to Silicon Valley's biotechnology companies and research institutions.

Key Challenges and Growth Opportunities in the United States Biologics Market

The United States biologics market faces challenges including the high cost and complexity of manufacturing infrastructure for biologic production, intensifying competition from biosimilar entrants that pressure originator biologic pricing, and stringent regulatory documentation requirements for biologic approvals.

Despite these challenges, the market offers considerable growth opportunities driven by strategic partnerships decentralizing manufacturing capabilities, continued expansion of AI-powered drug discovery and clinical trial optimization, and rising healthcare expenditure supporting patient access to advanced therapies. Continued investment in personalized medicine and next-generation bioprocessing technologies is expected to support long-term growth in the United States biologics market.

Competitive Landscape

Competition in the United States biologics market comes through key pharmaceutical and biotech innovators that continue investing heavily in research and development activities. Major players boast advanced portfolios for next-generation monoclonal antibodies, vaccines, and gene therapies, while emerging startups and contract research organizations contribute niche biologics development and outsourcing solutions. Strategic partnerships and acquisitions often serve as primary market-positioning strategies, with advances in manufacturing technologies and personalized medicine continuously reshaping the competitive landscape.

Recent Developments in the United States Biologics Market

  • September 2024: The FDA approved Dupixent (dupilumab) as the first biologic for inadequately controlled COPD with an eosinophilic phenotype, with Phase 3 trials showing exacerbation reductions of up to 34% and improved lung function and quality of life.
  • February 2024: Biocon Biologics Ltd signed a settlement and license agreement with Janssen Biotech to commercialize Bmab 1200, a biosimilar to Stelara (Ustekinumab), in the U.S. starting February 2025, pending FDA approval, resolving a patent dispute and supporting Biocon's immunology franchise expansion.
  • May 2024: Galapagos NV and Blood Centers of America entered into a partnership to decentralize CAR-T therapy manufacturing across 50 U.S. centers, ensuring rapid seven-day vein-to-vein delivery and enhancing scalability, physician control, and patient access.

Author IMARC Group

IMARC Group is a leading global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives. With a multidisciplinary team of industry experts, IMARC delivers reliable market intelligence across sectors including Chemicals and Materials, Healthcare, Technology, Agriculture, and Retail.

Contact Us:

IMARC Group

Email: [email protected]

United States: +1-201-971-6302